Los puntos clave no están disponibles para este artículo en este momento.
Since PSA screening and the treatment that may follow result in trading off one cause of death for another, rather than extending life, providers who support such screening should offer patients a better deal by protecting them from overdiagnosis and overtreatment.
Welch et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: